Q1 2023 13F Holders as of 3/31/2023
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
105M
-
Number of holders
-
215
-
Total 13F shares, excl. options
-
76.5M
-
Shares change
-
+2.99M
-
Total reported value, excl. options
-
$2.46B
-
Value change
-
+$118M
-
Put/Call ratio
-
0.28
-
Number of buys
-
109
-
Number of sells
-
-94
-
Price
-
$32.21
Significant Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) as of Q1 2023
263 filings reported holding RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q1 2023.
Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) has 215 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 76.5M shares
of 105M outstanding shares and own 73.11% of the company stock.
Largest 10 shareholders include Capital World Investors (10.1M shares), BlackRock Inc. (6.14M shares), Palo Alto Investors LP (5.27M shares), JPMORGAN CHASE & CO (5.16M shares), VANGUARD GROUP INC (4.6M shares), Polar Capital Holdings Plc (4.17M shares), D. E. Shaw & Co., Inc. (2.29M shares), FRANKLIN RESOURCES INC (2.27M shares), Thrivent Financial for Lutherans (2.02M shares), and ALLIANCEBERNSTEIN L.P. (1.98M shares).
This table shows the top 215 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.